Immunology

Shaperon is developing an innovative trispecific antibody that simultaneously targets CD3, 4-1BB, and tumor-associated antigens. This approach is based on the company’s proprietary NanoMab Antibody Development Platform, which aims to address unmet needs associated with conventional bispecific antibodies and antibody-drug conjugates (ADCs).

This strategy holds the potential to reduce adverse effects commonly associated with CD3 bispecific antibodies—such as cytokine release syndrome—while promoting sustained activation and survival of T cells through 4-1BB stimulation. Furthermore, by targeting specific tumor antigens, this platform is expected to elicit tumor-specific immune responses.